MNKD

Business Context and Reporting Period

Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on the Technosphere Insulin System for diabetes treatment and cancer immunotherapy candidates. The company has no commercial products and has not generated significant product revenue. As of September 30, 2006, the company had an accumulated deficit of $716.6 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Remained negligible ($100k for nine months 2006 vs. $0 for nine months 2005).
• Net Loss: Net loss for the nine months ended September 30, 2006, increased to $159.3 million from $81.0 million in the same period in 2005. This represents a 96% increase in losses.
• Operating Expenses:
  • R&D Expenses: Increased 98% to $132.1 million (nine months 2006) from $66.8 million (nine months 2005), driven by expanded Phase 3 clinical trials for Technosphere Insulin and manufacturing costs.
  • G&A Expenses: Increased 83% to $29.9 million (nine months 2006) from $16.3 million (nine months 2005), due to increased headcount, compliance costs, and the adoption of SFAS No. 123R.
• Stock-Based Compensation: The adoption of SFAS No. 123R on January 1, 2006, resulted in a significant increase in non-cash stock-based compensation expense ($10.7 million for the nine months ended Sep 30, 2006) compared to a benefit in the prior year.
• Liquidity: Cash and cash equivalents decreased from $56.0 million at December 31, 2005, to $43.1 million at September 30, 2006. Marketable securities dropped significantly from $89.6 million to $7.0 million as they were sold to fund operations.
• Debt: The company borrowed $50.0 million under a loan arrangement with its principal stockholder in August 2006, which was not present in the prior period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management believes the $50 million loan from the principal stockholder will fund operations through the first quarter of 2007. The company expects to need additional capital via equity/debt sales or strategic collaborations to continue development. A shelf registration statement for up to $500 million in securities was filed on November 2, 2006.
• Development Status: The Technosphere Insulin System is in Phase 3 clinical trials. The company plans to accumulate two years of controlled safety data before filing a New Drug Application (NDA). Enrollment for a pivotal two-year safety study was completed in September 2006.
• Unusual Items:
  • Related-Party Loan: A $150 million credit facility with principal stockholder Alfred E. Mann was established in August 2006. $50 million was drawn. Interest accrues at LIBOR + 3%.
  • Subsequent Event: On October 12, 2006, the company entered a licensing agreement with The Technion Research and Development Foundation Ltd., involving $3 million in license fees, issuance of 300,000 shares, and potential royalties.
• Risks:
  • Capital Needs: Failure to raise additional capital by Q1 2007 could force the reduction or discontinuation of operations.
  • Regulatory Approval: No assurance of FDA approval for Technosphere Insulin; the product is a combination drug/device requiring complex review.
  • Competition: Intense competition from inhaled insulin products (e.g., Pfizer's Exubera, Eli Lilly's AIR).
  • Litigation: Ongoing lawsuit with former Chief Medical Officer Dr. Wayman Cheatham seeking over $2 million in damages; trial scheduled for February 2007.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $43.1 million cash balance plus the $100 million remaining availability under the related-party loan to fund operations through Q1 2007.
• Capital Raising: Monitor the status of the $500 million shelf registration filed in November 2006 and any subsequent equity or debt issuances.
• Clinical Trial Progress: Track enrollment and safety data results from the pivotal Phase 3 trials, particularly the two-year pulmonary safety study.
• Related-Party Transactions: Review the terms of the loan with Alfred E. Mann and the new licensing agreement with The Technion for potential dilution or financial obligations.
• Litigation Status: Follow the outcome of the Cheatham lawsuit scheduled for trial in February 2007.
• Stock-Based Compensation: Assess the impact of SFAS No. 123R on future earnings, noting $37.1 million of unrecognized compensation cost remaining.